Celeste Bello, MD

Dr. Celeste Bello is a double board-certified hematologist and medical oncologist at Moffitt Cancer Center. She joined the faculty at Moffitt Cancer Center in 2008 after completing her fellowship at the University of South Florida. Dr. Bello has developed special expertise in managing patients with Hodgkin’s and non-Hodgkin’s lymphomas, a special category within the broader group of hematologic (blood) malignancies. Examples of non-Hodgkin’s lymphomas include follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. She is a current member of the National Comprehensive Cancer Network Hodgkin lymphoma guidelines panel. She also specializes in treating patients with central nervous system lymphomas. Dr. Bello is an active researcher in the field and can often offer her patients several options for clinical trials in addition to the standard therapies. She is very involved with the education of medical students and residents at the University of South Florida and at Moffitt Cancer Center. She is also a frequent lecturer on lymphomas for both medical and lay audiences, including presenting at Lymphoma Research Foundation events.

Provider

Celeste Bello, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Hematology
  • Medical Oncology
FELLOWSHIP:
  • University of South Florida - Hematology/Oncology
RESIDENCY:
  • University of South Florida - Internal Medicine
MEDICAL SCHOOL:
  • University of South Florida - MD
Provider

Celeste Bello, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Publications

  • Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr;8(4):129-138. Pubmedid: 28491264. Pmcid: PMC5405899.
  • Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S170-S174. Pubmedid: 27521314.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Ne. 2015 May;13(5):554-586. Pubmedid: 25964641. Pmcid: PMC4898052.
  • Eatrides J, Thompson Z, Lee JH, Bello C, Dalia S. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Ann Hematol. 2015 Feb;94(2):357-358. Pubmedid: 25034876.
  • Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb;125(9):1394-1402. Pubmedid: 25573987.
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May;123(22):3390-3397. Pubmedid: 24615777. Pmcid: PMC4123414.
  • Trimaldi JA, Bowers JW, Bello C, Sagatys EM. Follicular Lymphoma With Progression to Diffuse Large B-Cell Lymphoma and Concurrent CD5-Negative Mantle Cell Lymphoma-3 Entities in a Lymph Node. Cancer Control. 2014 Jul;21(3):251-254. Pubmedid: 24955711.
  • Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014 Aug;93(8):1305-1312. Pubmedid: 24590536.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.
  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.
  • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible?. Leuk Res Treatment. 2013 Nov;2013:629283. Pubmedid: 24288618. Pmcid: PMC3833187.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012 May;10(5):589-597. Pubmedid: 22570290.
  • Bello C, Zhang L, Naghashpour M. Follicular lymphoma: current management and future directions. Cancer Control. 2012 Jul;19(3):187-195. Pubmedid: 22710894.
  • Bello C, Sokol L. B-cell non-hodgkin lymphoma: targeting in on the future. Cancer Control. 2012 Jul;19(3):171-172. Pubmedid: 22710892.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J. Hodgkin lymphoma. J Natl Compr Canc Netw. 2011 Sep;9(9):1020-1058. Pubmedid: 21917626.
  • Bello C, Veliz M, Pinilla-Ibarz J. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Expert Rev Clin Immunol. 2011 May;7(3):295-300. Pubmedid: 21595596.
  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr;117(7):1463-1469. Pubmedid: 21425147. Pmcid: PMC4545502.
  • Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Curr Oncol Rep. 2008 Sep;10(5):365-371. Pubmedid: 18706263.

Provider

Celeste Bello, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 18361
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: Adcetris (Brentuximab vedotin); Adriamycin (doxorubicin); Brentuximab vedotin; DTIC (Dacarbazine); Dacarbazine; SGN-35 (Brentuximab vedotin)
Open

CLINICAL TRIAL 17967
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: KTE-C19; Levetiracetam; Tocilizumab; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18329
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Condition: Malignant Hematology
Intervention: KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18615
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation
Condition: Malignant Hematology
Intervention: Adcetris (Brentuximab vedotin); BMS-936558 (Nivolumab); Brentuximab vedotin; Nivolumab; SGN-35 (Brentuximab vedotin)
Open

CLINICAL TRIAL 18744
A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Condition: Malignant Hematology
Intervention: MEDI-570
Open

CLINICAL TRIAL 18816
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq); KTE-C19; Not Applicable; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18083
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m^2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m^2 SC/IV daily for 3 days every month) versus Azcitidine (AZA; 75 mg/m^2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
Condition: Malignant Hematology
Intervention: azacitidine (5-azacitidine); decitabine (5-aza-2'-deoxycytidine)
Open

CLINICAL TRIAL 18165
A Phase 1, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-Chop in Subjects with IPI 2 or More Previously Untreated Diffuse Large B-Cell Lymphoma or Grade 3B Follicular Lymphoma, or Transformed Lymphoma
Condition: Malignant Hematology
Intervention: Adriamycin (doxorubicin); CC-486 (Azacitidine (Oral)); Rituxan (rituximab); Vincristine; cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; prednisone; rituximab
Open

CLINICAL TRIAL 18858
A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
Condition: Malignant Hematology
Intervention: ALRN-6924
Open

CLINICAL TRIAL 17682
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Condition: Malignant Hematology
Intervention: CC-122; CC-223; CC-292; Rituxan (rituximab); rituximab
Open

CLINICAL TRIAL 19070
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19072
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18539
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); ACP-196 (Acalabrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Celeste Bello, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio